A. Xyrafas

发表

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2013, British Journal of Cancer.

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

K. Nackaerts, O. Riesterer, R. Stahel, 2015, The Lancet. Oncology.

Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.

K. Nackaerts, O. Riesterer, R. Stahel, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history.

V. Baracos, Z. Giannousi, V. Georgoulias, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

H. Rosing, C. Berset, H. Hawle, 2016, Haematologica.

Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study.

S. Agelaki, G. Kallergi, V. Georgoulias, 2010 .

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

S. Agelaki, G. Kallergi, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib

G. Kallergi, D. Mavroudis, V. Georgoulias, 2014, Cancer Chemotherapy and Pharmacology.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Angad P. Singh, A. Singh, A. Lesokhin, 2021, Journal for ImmunoTherapy of Cancer.

1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC).

R. Mirimanoff, R. Stupp, R. Stahel, 2014, Annals of Oncology.

Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).

R. Mirimanoff, R. Stupp, R. Stahel, 2013 .

Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.

R. Mirimanoff, R. Stupp, H. Ris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

R. Herrmann, H. Hawle, S. Dimitrijević, 2018, European journal of cancer.

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer

C. Tsatsanis, P. Vlachostergios, K. Kamposioras, 2013, Clinical and Translational Oncology.

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

L. Bubendorf, S. Peters, D. Betticher, 2019, British Journal of Cancer.

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long‐Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)

R. Mirimanoff, R. Stupp, R. Stahel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

R. Mirimanoff, R. Stupp, R. Stahel, 2015, The Lancet.

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

F. Hodi, G. Curigliano, A. Santoro, 2021, Clinical Cancer Research.

Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis

D. Mavroudis, V. Georgoulias, Z. Giannousi, 2012, Supportive Care in Cancer.

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

A. Stathis, M. Joerger, C. Catapano, 2017, Investigational New Drugs.

The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.

Z. Giannousi, P. Vlachostergios, V. Georgoulias, 2012, Lung cancer.

ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

V. Georgoulias, A. Voutsina, S. Agelaki, 2015, Cancer investigation.

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207).

J. Lemonnier, B. Thürlimann, H. Hawle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

S. Agelaki, G. Kallergi, D. Mavroudis, 2011, Breast Cancer Research.

Fifteen-year trends in metastatic breast cancer survival in Greece

U. Dafni, G. Fountzilas, A. Eleftheraki, 2010, Breast Cancer Research and Treatment.

Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy

G. Curigliano, A. Santoro, S. Gutzwiller, 2019, Annals of Oncology.

IMPACT OF EARLY PROPHYLACTIC CRANIAL IRRADIATION WITH HIPPOCAMPAL AVOIDANCE ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LIMITED DISEASE SMALL-CELL LUNG CANCER. A MULTICENTER PHASE II TRIAL (SAKK 15/12).

C. B. Rudolf, A. Allal, D. Aebersold, 2020, International journal of radiation oncology, biology, physics.

Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12).

D. Betticher, D. Aebersold, F. Caparrotti, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2014, Cancer Chemotherapy and Pharmacology.

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumor cells in patients with early breast cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2012, British Journal of Cancer.

Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients.

Matthias Guckenberger, Stephanie Tanadini-Lang, Jan Unkelbach, 2020, Medical physics.

Baseline comprehensive geriatric assessment (CGA) and prediction of toxicity in elderly non-small cell lung cancer (NSCLC) patients receiving chemotherapy.

S. Agelaki, V. Georgoulias, Z. Giannousi, 2011, Journal of Clinical Oncology.

EP-1910 CT image standardization is superior to larger but heterogeneous datasets for robust radiomic models

J. Unkelbach, S. Peters, M. Guckenberger, 2019, Radiotherapy and Oncology.

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

L. Bubendorf, S. Peters, D. Betticher, 2019, British Journal of Cancer.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

R. Mirimanoff, R. Stupp, R. Stahel, 2015, The Lancet.

H. Rosing, H. Hawle, A. Huitema, 2016, Haematologica.